Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide

Citations Over Time

Abstract

Considerable variation exists in the pharmacokinetics of LEV-XR in dogs with epilepsy being treated with a common dose regimen. Concurrent administration of phenobarbital contributed significantly to the variation. Other factors evaluated, including co-administration of zonisamide, were not shown to contribute to the variability. Drug monitoring may be beneficial to determine the most appropriate dose of LEV-XR in individual dogs.

Related Papers

• → Aspects of the Pharmacology of Phenytoin (Dilantin®) and Phenobarbital Relevant to their Dosage in the Treatment of Epilepsy(1959)84 cited
• → Interactions of Phenytoin and Phenobarbital in Terms of Order and Temporal Spacing of Administration in Monkeys(1976)8 cited
• → Effect of Zonisamide on Plasma Concentrations of Phenobarbital.(1998)
• [Blood levels of phenytoin and phenobarbital in epileptics treated with phenydantin and phenytoinum].(1978)
• → Epilepsy drugs levetiracetam and zonisamide should not be routinely used first line in the NHS, conclude researchers(2021)